Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Completed

• Conditions: Escherichia Coli Infections; Klebsiella Infections

• Registration Number: NCT00167986
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-09-11
• Study First Submitted QC: 2005-09-11
• Study First Posted: 2005-09-14
• Status Verified: 2007-03
• Last Update Submitted: 2007-03-14
• Last Update Posted: 2007-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

• All patients admitted to or transferred to the MICU.
• Patients 18 years of age or older.
• Provide written informed consent.

Exclusion Criteria

• Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae.
• Patients who have hypersensitivity to penicillin.
• Any underlying conditions or diseases that will be ultimately fatal within 48 hours.
• Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified